As of September 19, 2026, the GLP-1 litigation has moved forward under new leadership. Judge Gene E.K. Pratter, who had presided over the MDL, passed away in May 2026, and the case was reassigned to Judge Karen S. Marston in June 2026. The gastrointestinal-injury MDL (No. 3094) reported 4,022 pending cases as of September 1, 2026, while a newly separated vision-loss MDL (No. 3163) covering NAION claims reported 216 pending cases as of the same date. Summary judgment briefing on warning-adequacy issues was still underway in late August 2026. No bellwether trial has taken place yet, and no global settlement has been reached.
Last updated: September 2026
Thousands of people who took GLP-1 drugs like Ozempic and Wegovy are now part of one of the largest pharmaceutical mass torts in recent U.S. history. The GLP-1 lawsuit centers on claims that drug manufacturers Novo Nordisk and Eli Lilly knew about serious risks, including stomach paralysis and vision loss, but failed to warn patients adequately.
By early 2026, the GLP-1 Multidistrict Litigation contains well over 10,000 active cases. That number keeps climbing.
This article breaks down everything you need to know. What the lawsuit is actually about. Which drugs are named. Who can file. What settlements might pay. And what is happening in court right now.
One detail surprises most people: these lawsuits are not just about Ozempic. Wegovy, Mounjaro, and Zepbound are all part of this legal fight.
GLP-1 Lawsuit 2026: What Is Happening Right Now
The GLP-1 lawsuit in 2026 is an active, fast-moving mass tort litigation targeting two of the world’s largest pharmaceutical companies over injuries caused by a class of drugs known as GLP-1 receptor agonists.
As of 2026, the primary federal litigation is consolidated in the U.S. District Court for the Eastern District of Pennsylvania under MDL No. 3094. Federal Judge Gene E.K. Pratter oversees the proceedings.
Plaintiffs argue that Novo Nordisk and Eli Lilly knew their drugs could cause severe gastrointestinal injuries and serious vision damage. They argue the companies buried those risks and failed to put adequate warnings on labels.
The litigation is past the early filing stage. Courts are now deep into discovery, and bellwether trials are being scheduled to test the strength of plaintiff claims before any broad settlement talks begin.
| Key Detail | Current Status (2026) |
|---|---|
| MDL Case Number | MDL No. 3094 |
| Court Location | Eastern District of Pennsylvania |
| Presiding Judge | Judge Gene E.K. Pratter |
| Active Cases | 10,000+ and growing |
| Primary Defendants | Novo Nordisk, Eli Lilly |
| Stage | Discovery, bellwether trial prep |
This is not a closed case. It is an open and active litigation with significant developments expected throughout 2026.
What Is the GLP-1 Lawsuit
The GLP-1 lawsuit is a product liability and failure-to-warn legal action filed by patients who suffered serious medical injuries after using GLP-1 receptor agonist drugs prescribed for type 2 diabetes or weight management.
GLP-1 stands for glucagon-like peptide-1. These drugs work by mimicking a hormone that regulates insulin and slows how fast food leaves the stomach.
That stomach-slowing mechanism is exactly what is at the center of these lawsuits. When the stomach empties too slowly or stops working entirely, it causes a condition called gastroparesis. Some patients ended up hospitalized. Some required surgery.
The lawsuits also include people who lost partial or full vision after using these drugs. That specific injury is connected to a condition called Non-Arteritic Anterior Ischemic Optic Neuropathy, which is known by the acronym NAION.
The central legal claim is straightforward: the drug companies knew about these risks and did not warn patients or doctors clearly enough. That is the foundation of every case in this litigation.
Ozempic and Wegovy Lawsuit Explained
The Ozempic and Wegovy lawsuits are the most recognized part of the broader GLP-1 litigation, targeting Novo Nordisk’s two flagship semaglutide drugs used by tens of millions of people worldwide.
Ozempic was originally approved by the FDA in 2017 for type 2 diabetes. Wegovy was approved in 2021 for chronic weight management. Both contain semaglutide. They became extraordinarily popular, and prescriptions skyrocketed between 2021 and 2024.
The problem: as the patient population grew, reports of severe gastrointestinal injuries flooded into the FDA’s adverse event reporting system. Patients described waking up vomiting for weeks. Some could not eat solid food at all. Others had emergency hospitalizations.
What the lawsuits specifically claim is that Novo Nordisk’s drug labels underplayed these risks. The company reportedly had internal data showing gastrointestinal injury risks were serious and persistent, but the public label did not reflect the full picture.
Think of it like buying a car where the manual mentions “tire wear” but the manufacturer quietly knew the axle had a design defect. The inadequate warning is the legal problem.
| Drug | Manufacturer | Active Ingredient | Primary Use |
|---|---|---|---|
| Ozempic | Novo Nordisk | Semaglutide | Type 2 Diabetes |
| Wegovy | Novo Nordisk | Semaglutide | Weight Management |
| Rybelsus | Novo Nordisk | Semaglutide (oral) | Type 2 Diabetes |
| Mounjaro | Eli Lilly | Tirzepatide | Type 2 Diabetes |
| Zepbound | Eli Lilly | Tirzepatide | Weight Management |
All five drugs are subject to active GLP-1 lawsuit claims.
Novo Nordisk and Eli Lilly Lawsuits
Novo Nordisk and Eli Lilly are the two primary defendants in the GLP-1 litigation, facing tens of billions of dollars in potential exposure from thousands of personal injury claims.
Novo Nordisk is the Danish pharmaceutical giant behind Ozempic and Wegovy. It is one of the most profitable drug companies in the world. Its semaglutide drugs generated over $20 billion in annual revenue at their peak.
Eli Lilly manufactures Mounjaro and Zepbound, both of which contain tirzepatide, a dual GLP-1 and GIP receptor agonist. Eli Lilly entered the weight loss market aggressively starting in 2022 and gained enormous market share quickly.
Both companies have denied that their drugs cause the injuries alleged in these lawsuits. Their legal teams argue that the approved FDA labels adequately disclosed gastrointestinal risks and that other factors contributed to plaintiff injuries.
That defense argument, however, is being challenged in discovery. Plaintiffs’ attorneys have been seeking internal company documents to show what each manufacturer knew about injury risks and when they knew it.
The legal exposure for each company is significant. Analysts watching the litigation have suggested that any global settlement, if reached, could rank among the largest pharmaceutical settlements in U.S. history.
Key Takeaway: The GLP-1 lawsuit is a mass tort against Novo Nordisk and Eli Lilly, covering five drugs and over 10,000 active cases in federal court, with the central claim being inadequate warning labels.
GLP-1 Side Effects Linked to Lawsuits
The GLP-1 side effects at the center of these lawsuits are not minor digestive discomfort. They are severe, sometimes permanent medical conditions that changed patients’ lives.
The FDA has issued updated safety communications about some of these risks. Drug labels have been modified. But plaintiffs argue those modifications came too late and still do not go far enough.
Here are the primary injuries driving the litigation:
- Gastroparesis (stomach paralysis): The stomach stops moving food into the small intestine properly. Patients suffer severe nausea, vomiting, malnutrition, and in serious cases, require feeding tubes or surgery.
- Bowel obstruction: A partial or complete blockage in the intestines. This can be life-threatening and often requires emergency surgery.
- Intestinal ileus: The intestine stops moving temporarily or permanently. Causes severe pain and hospitalization.
- NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy): Sudden loss of blood flow to the optic nerve, causing permanent vision loss in one or both eyes.
- Aspiration pneumonia: When stomach contents are vomited and inhaled into the lungs, particularly dangerous for patients under anesthesia.
Each of these conditions has spawned its own track of plaintiffs. Some plaintiffs experienced multiple injuries simultaneously.
GLP-1 Gastroparesis Lawsuit
The GLP-1 gastroparesis lawsuit represents the largest category of claims in the litigation, with patients across the country alleging their stomach stopped functioning normally after using semaglutide or tirzepatide drugs.
Gastroparesis literally means “stomach paralysis.” The stomach’s muscles stop working at normal strength, which means food sits in the stomach far longer than it should. The results range from constant nausea to complete inability to eat.
For many plaintiffs, the injury did not resolve when they stopped taking the drug. Some patients report chronic gastroparesis that persists years after discontinuing Ozempic or Wegovy. That long-term nature significantly increases potential damage claims because the injury is ongoing and requires continued medical care.
The scientific debate is still active. Novo Nordisk’s position is that the GLP-1 mechanism intentionally slows gastric emptying as a therapeutic effect and that what plaintiffs call “gastroparesis” is a known, labeled consequence. Plaintiffs counter that there is a major difference between temporary slowing and permanent gastric paralysis.
| Gastroparesis Claim Details | Information |
|---|---|
| Primary Drugs Involved | Ozempic, Wegovy, Mounjaro, Zepbound |
| Key Medical Diagnosis Needed | Confirmed gastroparesis by gastric emptying study |
| Duration Requirement | Typically persistent symptoms beyond drug discontinuation |
| Average Hospitalization Rate | Multiple hospitalizations reported per plaintiff |
Medical records and gastric emptying study results are critical evidence for this claim type.
GLP-1 Vision Loss Lawsuit
The GLP-1 vision loss lawsuit is a separate and rapidly growing category of claims alleging that Ozempic and Wegovy use caused Non-Arteritic Anterior Ischemic Optic Neuropathy, a condition that permanently damages the optic nerve.
NAION is not a minor vision problem. It is a sudden, often painless loss of vision in one eye that can be permanent. The condition occurs when blood flow to the optic nerve is disrupted.
A significant study published in the journal JAMA Ophthalmology in 2024 reported that semaglutide users had a substantially elevated risk of developing NAION compared to patients taking other diabetes or weight loss medications. That study became a cornerstone piece of evidence for vision-loss plaintiffs.
The FDA acknowledged these reports and added language about optic neuropathy to semaglutide drug labels, but plaintiffs argue the warning is still buried and insufficient.
Vision loss claims are generally viewed as among the most serious in the litigation. Permanent blindness or severe vision impairment carries high damage values. Legal analysts expect vision-loss cases to command significantly higher individual settlement or verdict amounts compared to GI injury claims.
Bold fact: The 2024 JAMA Ophthalmology study found semaglutide users had approximately four times the risk of NAION compared to patients on non-GLP-1 medications.
GLP-1 Bowel Obstruction and Surgical Complication Claims
GLP-1 bowel obstruction lawsuits cover patients who developed intestinal blockages, ileus, or suffered aspiration-related injuries during medical procedures while taking semaglutide or tirzepatide drugs.
Bowel obstruction is a medical emergency. When the intestine is partially or fully blocked, it can cut off blood supply to sections of the bowel, leading to tissue death, perforation, and sepsis. Many plaintiffs in this category required emergency surgery.
A separate but related category involves patients who underwent surgery while on GLP-1 drugs without knowing the risk. Because these drugs slow stomach emptying dramatically, anesthesiologists warn that patients may have full stomachs even after a standard pre-surgery fasting period. If a patient vomits under anesthesia, stomach acid can enter the lungs. This causes aspiration pneumonia, which can be fatal.
The American Society of Anesthesiologists issued guidelines in 2023 addressing GLP-1 drugs and surgery prep. Many plaintiffs argue they were never told to stop the medication before their procedures.
| Claim Type | Injury | Common Scenario |
|---|---|---|
| Bowel Obstruction | Intestinal blockage, emergency surgery | Ongoing GLP-1 use, sudden obstruction |
| Ileus | Intestinal paralysis | Post-operative complication |
| Aspiration Pneumonia | Lung injury from inhaled vomit | Surgery without stopping GLP-1 drug first |
This category overlaps with medical malpractice in some cases, where prescribers failed to advise stopping the drug before procedures.
Key Takeaway: GLP-1 lawsuit claims fall into three major injury tracks: gastroparesis, vision loss (NAION), and bowel obstruction or surgical complications. Each track has different medical evidence requirements and different potential settlement values.
Who Qualifies for the GLP-1 Lawsuit
You may qualify for the GLP-1 lawsuit if you used Ozempic, Wegovy, Mounjaro, Zepbound, or Rybelsus and were subsequently diagnosed with a qualifying serious medical condition.
General qualification requires a few core elements. You must have taken a GLP-1 drug. The drug must have been prescribed to you (not taken off-label without prescription). You must have suffered a documented medical injury from the list of covered conditions. And that injury must have required medical treatment, not just mild discomfort.
Here is a general qualifying framework:
- Drug used: Ozempic, Wegovy, Mounjaro, Zepbound, or Rybelsus
- Injury suffered: Gastroparesis, NAION (vision loss), bowel obstruction, intestinal ileus, or aspiration pneumonia
- Medical documentation: Hospital records, physician diagnosis, gastric emptying study results, ophthalmology records
- Prescription history: You must have a valid prescription record for the drug
- Timeframe: Most injuries link to use starting from approximately 2017 onward for semaglutide, 2022 onward for tirzepatide
People who experienced only mild nausea or temporary digestive upset that resolved quickly are generally not strong candidates for these lawsuits. The litigation focuses on serious, documented, and persistent injuries.
Using a GLP-1 drug off-label for weight loss before it was FDA-approved for weight management can still qualify, provided you had a valid prescription.
GLP-1 Lawsuit Eligibility Requirements
The GLP-1 lawsuit eligibility requirements go beyond just taking the medication. Plaintiffs need specific medical documentation to support a valid claim.
Medical proof is non-negotiable. Courts and defense teams will scrutinize every plaintiff’s medical records. Vague symptoms without a clinical diagnosis will not survive.
The core eligibility requirements in 2026 are:
- Confirmed diagnosis: A physician must have formally diagnosed you with gastroparesis, NAION, bowel obstruction, or another covered condition.
- Causal link: Your medical records must show temporal connection between GLP-1 drug use and onset of the injury.
- Prescription documentation: Pharmacy records or physician records showing you were prescribed and filled the medication.
- Treatment history: Evidence you sought and received medical treatment for the injury. Emergency room visits, hospitalizations, specialist consultations, and procedures all strengthen eligibility.
- Statute of limitations compliance: Your claim must be filed within the applicable time window for your state.
| Requirement | What You Need |
|---|---|
| Qualifying Drug | Prescription for Ozempic, Wegovy, Mounjaro, Zepbound, or Rybelsus |
| Qualifying Injury | Gastroparesis, NAION, bowel obstruction, ileus, aspiration pneumonia |
| Medical Records | Hospital, physician, specialist records showing diagnosis |
| Pharmacy Records | Proof of prescription fill history |
| Legal Deadline | Varies by state, typically 2 to 4 years from injury discovery |
Families of patients who died from complications related to these injuries may also qualify to file wrongful death claims.
GLP-1 Lawsuit Settlement 2026
No global GLP-1 lawsuit settlement has been reached as of early 2026, but settlement negotiations are expected to intensify as bellwether trial results emerge throughout the year.
This is normal for mass tort litigation of this scale. Settlements in large pharmaceutical MDLs almost never happen until after bellwether trials give both sides a realistic picture of what juries will do.
The MDL bellwether trials scheduled for 2026 will function as test cases. If juries return large verdicts for plaintiffs in those trials, Novo Nordisk and Eli Lilly face enormous pressure to settle. If trials go poorly for plaintiffs, settlement values compress.
Watch for these settlement indicators in 2026:
- Bellwether verdict amounts and which injury categories won
- The number of new cases being filed each month (an increase signals plaintiff confidence)
- Public statements from Novo Nordisk and Eli Lilly about litigation reserves in earnings calls
- Any Plaintiff Steering Committee announcements about global resolution discussions
Settlements in comparable pharmaceutical mass torts, like the Roundup glyphosate litigation or the 3M earplug MDL, reached settlement figures in the billions of dollars. Legal observers tracking the GLP-1 litigation expect similar territory if plaintiffs win early bellwether trials.
Bold fact: The largest pharmaceutical product liability settlement in U.S. history, the opioid settlement, exceeded $26 billion. The GLP-1 litigation involves patient populations in the tens of millions.
Key Takeaway: No GLP-1 settlement exists in early 2026. Settlement talks are expected to follow bellwether trial results later in 2026 or into 2027. The outcome of those trials will set the compensation tone.
How Much Will a GLP-1 Lawsuit Pay
GLP-1 lawsuit payouts will vary significantly based on injury severity, duration of harm, medical costs, and the outcome of bellwether trials, with estimates ranging from tens of thousands to several hundred thousand dollars per serious case.
Mass tort settlements work on a tiered point system. The more severe and permanent your injury, the higher your tier, and the larger your individual payout. Think of it like insurance adjusters categorizing claim severity, except the scale is much larger and the injuries far more serious.
Here is a general estimated tier structure based on comparable pharmaceutical mass tort precedents:
| Injury Severity Tier | Example Conditions | Estimated Individual Payout Range |
|---|---|---|
| Tier 1 (Moderate) | Gastroparesis requiring hospitalization, resolved | $25,000 to $75,000 |
| Tier 2 (Significant) | Chronic gastroparesis, ongoing treatment, surgery | $100,000 to $300,000 |
| Tier 3 (Severe) | Permanent NAION vision loss, major surgery complications | $300,000 to $1,000,000+ |
| Wrongful Death | Death linked to GLP-1 injury | Case-specific, potentially $1,000,000+ |
These are estimates based on comparable litigation. They are not guaranteed amounts.
Factors that will increase an individual payout include: younger age at time of injury, permanent rather than temporary impairment, high documented medical costs, strong causation evidence, and inability to work due to the injury.
Attorney contingency fees in mass tort cases typically run 33% to 40% of the gross settlement. That amount is deducted before the plaintiff receives their net payment.
GLP-1 MDL Update 2026
The GLP-1 MDL, formally known as MDL No. 3094 In Re: Ozempic (Semaglutide) Products Liability Litigation, is the centralized federal proceeding managing thousands of GLP-1 drug injury lawsuits from across the country.
An MDL is not a class action. Each plaintiff retains their own individual case. The MDL process groups them together for pretrial proceedings like discovery, expert witness depositions, and pretrial motions. This avoids 10,000 judges making 10,000 different rulings on the same legal questions.
As of 2026, the MDL has completed the initial case management order phase. The Plaintiff Steering Committee has been appointed. Defense fact discovery from Novo Nordisk and Eli Lilly is ongoing or recently completed.
Key 2026 MDL developments to watch:
- Expert witness challenges (Daubert hearings): The defense will attempt to exclude plaintiffs’ medical experts. These hearings often determine whether a case can go to trial.
- General causation rulings: The judge may issue rulings on whether scientific evidence sufficiently links GLP-1 drugs to specific injuries across all cases.
- Case-specific discovery: Individual plaintiff medical records are being collected and reviewed in preparation for bellwether selection.
The MDL proceeding moves in phases. Where it stands in 2026 puts the litigation roughly at the midpoint between mass filing and eventual resolution.
| MDL Phase | Description | Status (2026) |
|---|---|---|
| Initial Filing | Cases transferred to MDL court | Complete |
| Leadership appointment | Plaintiff Steering Committee formed | Complete |
| Discovery | Document exchange, depositions | Active / Near Complete |
| Daubert Hearings | Expert admissibility challenges | Scheduled / Pending |
| Bellwether Trials | Test cases to gauge jury response | Scheduled 2026 |
| Global Settlement Talks | Potential resolution discussions | Expected post-bellwether |
GLP-1 Bellwether Trials 2026
GLP-1 bellwether trials are the test cases scheduled for 2026 that will go before actual juries, giving both sides a real-world read on how these cases perform in court.
A bellwether trial is not binding on other plaintiffs. If a plaintiff wins a $500,000 verdict in a bellwether trial, that does not mean every plaintiff gets $500,000. What it does is set the temperature of the litigation. It tells lawyers on both sides what facts resonate with juries. It tells the drug companies how much risk they face if the litigation goes to trial at scale.
The cases selected for bellwether trials are chosen carefully. They are meant to be representative. Typically, a few plaintiff-friendly cases and a few defense-friendly cases are selected to cover the range.
In GLP-1 bellwether trials, the key battleground issues will be:
- Causation: Can plaintiffs prove their injury was caused specifically by the GLP-1 drug, not a pre-existing condition?
- Warning adequacy: Were the drug labels adequate to warn doctors and patients, or were they intentionally vague?
- Company knowledge: Did Novo Nordisk or Eli Lilly know about injury risks before patients did?
- Damages: What is the full economic and non-economic impact of the injuries on individual plaintiffs?
Bellwether trial results in comparable mass torts like the Roundup litigation triggered multi-billion dollar settlement discussions within months of plaintiff victories.
Key Takeaway: The GLP-1 bellwether trials scheduled for 2026 are the single most important factor in determining whether and at what value a global settlement will be reached. A plaintiff win triggers settlement pressure. A defense win delays resolution.
How to File a GLP-1 Lawsuit
Filing a GLP-1 lawsuit in 2026 involves connecting with a mass tort attorney, completing an intake evaluation, gathering your medical and prescription records, and submitting a Plaintiff Fact Sheet to the MDL court.
You do not file directly into the MDL yourself. Mass tort plaintiffs work through attorneys, who file individual lawsuits in the appropriate federal court. Those cases are then transferred to the MDL in Pennsylvania for coordinated pretrial management.
Here is the filing process step by step:
- Contact a mass tort law firm reviewing GLP-1 claims. Most offer free case evaluations.
- Complete an intake screening. You will be asked about which drug you took, how long you took it, and what medical injuries you experienced.
- Gather your records. Pharmacy prescription records, hospital discharge summaries, physician diagnosis records, specialist visit notes, and any test results like gastric emptying studies or ophthalmology reports.
- Sign a retainer agreement. Mass tort attorneys work on contingency, meaning no upfront cost. They collect a percentage of your recovery.
- Your attorney files a complaint. A formal lawsuit is filed on your behalf, typically in federal court.
- Your case is transferred to the MDL. The Judicial Panel on Multidistrict Litigation moves your case to the Pennsylvania MDL for consolidated management.
- Complete your Plaintiff Fact Sheet. This is a detailed document every MDL plaintiff must fill out, covering your medical history, drug use history, and injuries.
| Step | Action Required | Timeframe |
|---|---|---|
| Case evaluation | Contact a mass tort law firm | Day 1 |
| Record gathering | Pharmacy, hospital, physician records | 2 to 6 weeks |
| Filing complaint | Attorney files on your behalf | Within days of signing retainer |
| MDL transfer | Automatic once federal complaint filed | 30 to 90 days |
| Plaintiff Fact Sheet | Complete detailed questionnaire | Per court order deadline |
The earlier you file, the more time your attorney has to prepare your individual case file before bellwether selections are made.
GLP-1 Lawsuit Update and Current Status
The GLP-1 lawsuit in 2026 is at an active and consequential stage, with discovery winding down, Daubert hearings approaching, and bellwether trial dates locking in for the most significant legal tests the litigation has seen.
New cases continue to be filed at a substantial rate. The patient population that took these drugs is enormous. Estimates suggest tens of millions of Americans have used a GLP-1 drug at some point since 2017. Even a fraction of those experiencing serious injuries translates to a massive plaintiff pool.
Regulatory activity continues alongside the litigation. The FDA has updated drug labels multiple times in response to adverse event reports. Each label update, while helping future patients, simultaneously works against the manufacturers in court. It is hard to argue a risk was unknown when the FDA eventually required you to add it to the label.
Key status points as of 2026:
- MDL case count: Exceeding 10,000 with new cases added weekly
- Discovery status: Fact discovery from manufacturers is active or near completion
- Expert witnesses: Both sides preparing expert reports for Daubert challenges
- Bellwether selection: Specific trial cases being identified or already announced
- FDA label status: Warnings updated to include NAION reference and reinforced GI risk language
- Settlement status: No global settlement; individual cases not being resolved outside of the MDL framework yet
The litigation is not going away. Both sides are deeply invested. Novo Nordisk and Eli Lilly have the resources to fight for years. But the plaintiff numbers and the medical evidence are both growing, which creates increasing settlement pressure.
Watching the first bellwether trial results will tell you more about where this litigation is headed than any press release from either company.
Frequently Asked Questions
Who qualifies to file a GLP-1 lawsuit in 2026?
You likely qualify if you took Ozempic, Wegovy, Mounjaro, Zepbound, or Rybelsus and were diagnosed with gastroparesis, NAION vision loss, bowel obstruction, or a related serious medical condition.
You need a valid prescription record and medical documentation confirming your diagnosis.
Mild or temporary digestive discomfort alone is typically not sufficient to qualify.
How much money can you get from a GLP-1 lawsuit settlement?
No global settlement has been reached yet in 2026, so exact payout amounts are not confirmed.
Based on comparable pharmaceutical mass tort settlements, serious GLP-1 injury claims could yield individual payouts ranging from $25,000 for moderate hospitalized injuries to over $300,000 for permanent conditions like vision loss.
Final amounts depend on injury severity, medical expenses, and bellwether trial outcomes.
What drugs are included in the GLP-1 lawsuit?
The GLP-1 lawsuit currently covers five drugs: Ozempic, Wegovy, and Rybelsus (all semaglutide from Novo Nordisk), and Mounjaro and Zepbound (both tirzepatide from Eli Lilly).
All five are GLP-1 receptor agonists prescribed for diabetes management or weight loss.
Other GLP-1 drugs may be included in related litigation as more cases are evaluated.
What is the current status of the GLP-1 MDL in 2026?
The GLP-1 MDL (No. 3094) is in the active discovery and pre-trial phase as of 2026, with bellwether trials expected to begin during the year.
Discovery from Novo Nordisk and Eli Lilly is ongoing, and expert witness challenges are upcoming.
No global settlement is in place, but settlement discussions are expected to follow the first bellwether trial verdicts.
How long do you have to file a GLP-1 lawsuit?
The deadline to file a GLP-1 lawsuit depends on the statute of limitations in your state, which typically ranges from two to four years from the date you discovered your injury.
In most states, the clock starts when you were diagnosed with the qualifying condition, not necessarily when you started taking the drug.
Filing sooner is better. Delays can result in losing your legal right to participate entirely.
What Comes Next for GLP-1 Plaintiffs
The GLP-1 litigation is at the stage where the most consequential decisions are about to be made. Bellwether trials in 2026 will define the value of every case in this MDL.
If you or someone you care about took Ozempic, Wegovy, Mounjaro, or another GLP-1 drug and suffered serious health consequences, the time to evaluate your legal options is now. Not because of artificial urgency, but because statutes of limitations are real deadlines with permanent consequences.
Check your diagnosis records. Pull your prescription history. Connect with a mass tort attorney who handles pharmaceutical cases. Those three steps are where every GLP-1 lawsuit starts.
